Pick of the day
Alethio Therapeutics
Develops disease-modifying antibody therapies that aim to eliminate the mutant stem cells driving myeloproliferative neoplasms, a group of chronic blood cancers, rather than just managing their symptoms.
- Problem
- 7
- Traction
- 4
- Founders
- 8
- Market
- 6
- Novelty
- 6
Why today
Today's pick is Alethio Therapeutics, an Oxford spin-out that announced on November 6, 2026 an oversubscribed 80.46 million euro, roughly 90 million dollar, Series A to advance two antibody programs for myeloproliferative neoplasms, a family of chronic blood cancers that current drugs only manage rather than cure. What stands out is less the size of the round than the pedigree behind it: the company was founded by two Oxford physician-scientists who have spent their careers treating these diseases, its lead antibody targets a protein found almost exclusively on the cancer-driving stem cells themselves, and its preclinical data were strong enough to earn an oral presentation slot at this year's American Society of Hematology meeting before the company has dosed a single patient.
Problem
Myeloproliferative neoplasms are chronic blood cancers, including essential thrombocythaemia, in which mutated stem cells overproduce blood cells, raising the risk of dangerous clots, bleeding and eventual progression to myelofibrosis or acute leukemia. The standard treatments, hydroxycarbamide and interferon, are decades-old cytoreductive agents that lower blood counts broadly rather than targeting the mutant cells specifically, so they come with side effects and do not stop the disease from advancing. Patients can live with the condition for years, but face a slowly rising burden of symptoms and risk, and physicians have had no approved therapy that meaningfully changes that trajectory rather than just dampening its symptoms.
Product
Alethio's lead program, ATX-011, is a first-in-class monoclonal antibody targeting G6B, a protein the company says is found on the mutant stem and progenitor cells that drive myeloproliferative neoplasms, as well as on megakaryocytes and platelets, but not on healthy blood stem cells. The goal is to deplete the disease-driving cells selectively while sparing normal blood production, rather than suppressing blood counts across the board. A second program targets cells carrying mutant calreticulin, a mutation present in roughly 30 percent of myeloproliferative neoplasm patients. Both programs come out of the company's in-house ARTEMIS platform, which it uses to identify and validate new disease-driving targets in blood cancers.
Traction
Alethio has not yet dosed a patient; its evidence so far is preclinical. ATX-011 is in IND-enabling studies ahead of a planned Phase 1/2a trial in essential thrombocythaemia, and its preclinical data were selected for an oral presentation at the American Society of Hematology's 2026 annual meeting, a notable vote of scientific confidence for a company that has not yet entered the clinic. The company has not disclosed patient numbers, revenue or clinical efficacy data, since none exists yet; the near-term milestones to watch are IND clearance and the start of first-in-human dosing for ATX-011.
Team
Alethio was founded in 2021 as a spin-out from the University of Oxford by Professors Adam Mead and Beth Psaila, physician-scientists who specialize in treating myeloproliferative neoplasms and whose research informed the company's choice of targets. CEO Dr. Rohit Batta leads day-to-day operations. The round adds Graziano Seghezzi, managing partner at Sofinnova Partners, and Maxwell DeNies of RA Capital to the board, pairing the founders' deep clinical and academic grounding in the disease with investors experienced in advancing biotech companies from preclinical work into human trials.
Funding
Alethio's Series A was announced November 6, 2026 at 80.46 million euros, equivalent to roughly 90 million dollars, and the company said the round was oversubscribed. It was led by new investors Sofinnova Partners and RA Capital, with founding investor Oxford Science Enterprises also participating alongside Cancer Research Horizons and the University of Oxford. The company says the capital will fund its transition into a clinical-stage business, take ATX-011 through Phase 1/2a studies in essential thrombocythaemia and toward a Phase 3 trial, and advance its calreticulin-targeted program and other pipeline candidates toward IND submission.
Competitors
The mutant-calreticulin side of Alethio's pipeline sits in a crowded field: Incyte has an antibody, INCA033989, in development against mutant calreticulin, Janssen is pursuing a similar target with JNJ-88549968, Meiji Seika Pharma is developing a T-cell engager against mutant calreticulin, and Prelude Therapeutics has both a calreticulin-targeted antibody-drug conjugate and a JAK2V617F program that it has optioned to Incyte. Alethio's point of differentiation is its G6B-targeted lead program, which goes after a broader population of myeloproliferative neoplasm patients than calreticulin-mutant disease alone, plus a two-target pipeline rather than a single bet on one mutation.
VC lens
Would YC fund it? The question doesn't quite fit a capital-intensive, preclinical biotech led by domain-expert professors rather than first-time founders, but on the merits the answer is yes: a differentiated, mechanistically sound target, physician-scientist founders who treat the disease themselves, and an oversubscribed round from specialist biotech investors are exactly the signal YC looks for, just arriving through a different funding path.
Biggest risk: Alethio's biggest risk is translation: ATX-011 has only preclinical data, and myeloproliferative neoplasms have seen promising early-stage antibodies falter in the clinic before, while well-funded rivals like Incyte, Janssen and Prelude are racing toward the same calreticulin-mutant patient population Alethio's second program targets.
Runners-up
TEKEVER
A Portuguese maker of AI-driven autonomous defense and security systems, which closed its 580 million dollar Series D after Denmark's state investment fund EIFO joined the round at a 6.4 billion dollar valuation, ahead of a new Nordic hub in Odense. (Nov 6)
Candi Solar
A Zurich-based clean energy platform serving commercial and industrial customers in India and South Africa, which secured a 44 million euro financing facility from Pentagreen Capital and a consortium of development banks to fund 400 megawatts of solar and battery storage projects in India. (Nov 6)
Return
An Amsterdam-based battery storage developer and operator, which secured 835 million euros in portfolio financing underwritten by Deutsche Bank and Rabobank to expand large-scale battery storage capacity across Germany. (Nov 4)
Clinics On Cloud
A Pune-based health-tech startup building AI-powered health ATMs and mobile microclinics, which raised a 12.5 million dollar Series A from Dubai's Model42 at a 63.3 million dollar valuation to expand into the UAE, Africa and Southeast Asia. (Nov 3)
Archive
68 reports · click a row to open it| Date | Winner | One-liner | Runners-up | Open |
|---|---|---|---|---|
| 2026-11-18 | Isomorphic Labs | 5 billion dollar Series C co-led by Greenoaks and Sequoia Capital, as the DeepMind spinout led by Nobel laureate Demis Hassabis pushes its AlphaFold-derived AI drug design engine toward clinical trials with preclinical wins in oncology and immunology and deals with Eli Lilly, Novartis and Johnson & Johnson | Model ML, Genesis AI, Mirendil, Torus | |
| 2026-11-17 | Corma | 125 million dollar Series A led by NEA at a 1 billion dollar valuation, just three months after its 60 million dollar seed, as the Tel Aviv and San Francisco startup trains foundation models exclusively for defensive cybersecurity instead of retrofitting general-purpose AI built for offense | Remedy Robotics, Stark Future, Dreamteam, Bedrock Energy | |
| 2026-11-16 | Lumbra | 25 million dollar Series A co-led by Point72 Ventures and Ansa Capital, as the Washington DC startup's agentic AI operating system already runs in production on top-secret US government networks and the Pentagon names it one of two companies, alongside Palantir, powering its Agent Network project | Alta, Blue J, Sparxity, Reflect Orbital | |
| 2026-11-15 | Path Robotics | 300 million dollar Series E led by Georgian at a 2.45 billion dollar valuation, as the Columbus, Ohio startup's AI model for tracking and correcting weld distortion in real time grows annualized revenue 17x in 18 months on a 600 million dollar HII Navy shipbuilding deal | Graphon Labs, Hypersonica, Nominal, T-Therapeutics | |
| 2026-11-14 | Nebuly | 21 million dollar Series A led by Planven as the Turin founded startup's platform for measuring the business ROI of enterprise AI agents already tracks usage for Global 2000 companies in banking, healthcare, telecom and manufacturing | Mercor, Mondrio, Opdo, Palomma | |
| 2026-11-13 | UFORCE | 700 million dollar Series A at a 6 billion dollar valuation co-led by Valor Equity Partners and the UK National Wealth Fund, as the London headquartered, Ukrainian rooted defence startup's autonomous ships and drones add combat proven results from sinking Russian warships to 300,000 drone combat flights | Agile Robots, Griffin, Biomatter, Gama | |
| 2026-11-12 | Fractile | Over 500 million pound Series C at a valuation above 5 billion pounds led by Thrive Capital, Founders Fund, Lightspeed and Redpoint, as the London chip startup's bet on in-memory inference chips to run large language models up to 100 times faster and 90 percent cheaper sees its valuation grow sixfold in six months | sennder, Tendrils Compute, Kardi Ai, Anorak | |
| 2026-11-11 | Sumary | 25 million dollar seed round led by Singular, as the Copenhagen AI-native accounting platform gets adopted by most of the Nordics' twenty largest accounting firms plus UK names Deloitte, Grant Thornton and Baker Tilly just three months after launch | PORT, Ancep, triPica, Danish Centre for AI Innovation | |
| 2026-11-10 | Onodrim Industries | 300 million dollar Series A at a 1.3 billion dollar valuation led by Lux Capital, as the Palantir-alumni-founded platform sets out to buy and modernize Europe's fragmented defense and industrial suppliers | Marble Imaging, SRTD Biotech, Claimlane, Peppermint Robotics | |
| 2026-11-09 | Alethio Therapeutics | 80.46 million euro (about 90 million dollar) oversubscribed Series A led by Sofinnova Partners and RA Capital, as the Oxford spin-out advances a first-in-class antibody targeting the mutant stem cells behind myeloproliferative neoplasms toward its first human trial | TEKEVER, Candi Solar, Return, Clinics On Cloud | |
| 2026-11-08 | Zipline | 1.5 billion dollar round at a 21.5 billion dollar valuation led by Paradigm, WCM Investment Management and Layer Global, as the autonomous drone delivery company signs a new multi-year Walmart deal to add up to 300 US delivery sites | Applied Compute, Tutor Intelligence, Kalepa, CesiumAstro | |
| 2026-11-07 | Physicl | 10 million dollar seed round led by Inovia Capital with participation from US Venture Partners, as the Paris and San Francisco based startup pairs synthetic edge-case generation for robots and world models with independent third-party validation of its accuracy | Infisical, TrashLab, Samplix, Braid | |
| 2026-11-06 | Harbinger | 240 million dollar Series D co-led by Tiger Global, Capricorn and defense-focused investor Ridgeline, pushing total funding past 650 million dollars as the electric truck maker that landed a 300 million dollar FedEx order expands its platform into driverless military vehicles | Titan OS, EloElo Group, altM, Cosmoserve Space | |
| 2026-11-05 | fal | 1.3 billion dollar Series F led by Bessemer Venture Partners at a 16 billion dollar valuation, doubling in seven months as the generative media infrastructure platform's annualized revenue reportedly doubled to 800 million dollars serving Adobe, Canva, Perplexity and Shopify | Supa, Lazzaro One, Peppermint Robotics, GIVA | |
| 2026-11-04 | FuriosaAI | 620 million dollar Series D led by South Korea's National Growth Fund at a 2.9 billion dollar valuation, as the Seoul based AI inference chip maker ships RNGD accelerators already running inside Samsung SDS and LG Group data centers | Fractile, Kalshi, Opentrons, Easol | |
| 2026-11-03 | Northwood Space | 375 million dollar Series C co-led by Andreessen Horowitz and DFJ Growth at a 2 billion dollar valuation, as the mass-producible satellite ground station startup backs its hardware with a nearly 50 million dollar U.S. Space Force contract | Trajectory, Hypersonica, LO:TECH, Roleo | |
| 2026-11-02 | Serval | 150 million dollar Series C led by Sequoia Capital at a 3 billion dollar valuation, triple its level five months ago, as the AI-native challenger to ServiceNow converted two Fortune 20 companies and doubled revenue every quarter since its Series B | Kalshi, Mintive, MP Space, Dulo | |
| 2026-11-01 | Upwind | 400 million dollar Series C led by Bessemer Venture Partners at a 3.8 billion dollar valuation, as the cloud and AI security startup quadrupled revenue and turned down a near 4 billion dollar acquisition offer from Datadog | Circuit Mind, Plato, Easol, Re:Build Manufacturing | |
| 2026-10-31 | Hyperbolic | 30 million dollar Series A-1 led by Intel CEO Lip-Bu Tan's Walden Catalyst, as the AI compute marketplace aggregating 30 cloud providers into one dashboard pushes toward letting idle GPU capacity trade like electricity | Braid, Bites, Midstream Health, Crux Labs | |
| 2026-10-30 | Dream | 17 million dollar seed round led by Andreessen Horowitz, as the ex-Palantir founders' AI world models took on architect-of-record liability for commercial buildings already under construction in Texas and California | Ravical, VUSE XR, KineDB, Ace Blend | |
| 2026-10-29 | Numeracle | 28 million dollar growth investment from Edison Partners, as the profitable McLean, Virginia company's business identity verification tools kept legitimate calls from 4,000 customers from being wrongly flagged as spam | Machenta, Vera Health, Autofixer, Zorit | |
| 2026-10-28 | Simplismart | 14 million dollar Series B led by Dallas Venture Capital with Nvidia participating, as the Bengaluru AI inference startup's annualised revenue run rate grew 14x in six months on the back of US customers like HeyGen and Shiprocket | Nova Spectral AI, Live2.ai, Mochatrade, Troovy | |
| 2026-10-27 | Bedrock Robotics | 600 million dollar Series C co-led by CapitalG and Emergence Capital at a 4.1 billion dollar valuation, as the Waymo-founded startup's retrofit kit for autonomous excavators moved from pilots to paid commercial work on job sites in Nevada, Texas and Arizona | Matiks, Nous, adsilico, Volare | |
| 2026-10-26 | Blacksmith | 66 million dollar Series C led by Sequoia Capital at a 1 billion dollar valuation, as the YC-backed CI platform's weekly jobs run grew from 5 million to over 90 million amid a flood of AI-written code | Enact Intelligence, QuantrolOx, Beyond Vision, Maxinsights | |
| 2026-10-25 | Flapping Airplanes | 1 billion dollar Series A at a 6 billion dollar valuation co-led by Index Ventures and Lux Capital, as the year-old AI efficiency lab's valuation quadrupled nine months after its seed with still no shipped product | Air Space Intelligence, Whop, Arda Industries, AuxoAI | |
| 2026-10-24 | CureBay | 100 crore rupee Pre-Series C led by IvyCap Ventures, as the rural healthcare startup's network of technology enabled clinics and community health workers across seven Indian states passes 1.7 million patients served | Slingshot Insurance, Firstwork, Karta AI, Chapter Home | |
| 2026-10-23 | Warhound | 200 million dollar round at a 1.2 billion dollar valuation from In-Q-Tel, Sequoia and 8VC, as Colossal Biosciences founder Ben Lamm and Anduril co-founder Palmer Luckey launch a company that genetically engineers and clones working dogs for the military and arms them with Anduril sensor gear | Enact, Beyond Vision, QuantrolOx, Indurex | |
| 2026-10-22 | Legora | 550 million dollar Series E at an 8.8 billion dollar valuation led by Atreides Management, as the legal AI company's annual recurring revenue doubled past 200 million dollars in six months while US in-house legal teams became its fastest-growing customer base | Pigment, Opply, Photon Bridge, Blacksmith | |
| 2026-10-21 | Daytona | 60 million dollar Series B at a 1 billion dollar valuation led by FirstMark, as the AI agent sandbox company's revenue run rate rose twenty-five fold in nine months on a customer list including Anthropic, OpenAI, Nvidia, Cursor, Cognition and Meta | Blackwall, Vessla, Linkener, Coherence Quantum | |
| 2026-10-20 | Tenstorrent | 1.5 billion dollar round at a 6.2 billion dollar valuation, more than doubling its 2024 mark, as chip architect Jim Keller's inference-chip startup turns down Intel and Qualcomm buyout interest to keep challenging Nvidia independently | Town, Hunar.AI, Rabot Energy, Otter Health | |
| 2026-10-19 | Modal Labs | 750 million dollar Series D led by Accel at a 15.75 billion dollar valuation, as the AI infrastructure startup says its annualized run rate crossed 1 billion dollars with usage tripling in five months, built on serverless GPU access for inference, training and agent sandboxes | OMass Therapeutics, Scanntech, North.cloud, Fortem Technologies | |
| 2026-10-18 | Mueon | 65 million dollar Series A led by Maverick Silicon, as the Portland semiconductor startup founded by two Intel veterans scales Cubelets, modular 3D blocks bundling compute, memory, power and cooling to cut AI data center power and density limits, already in use by AI chip startup d-Matrix | Estuary Biotherapeutics, Fission, Otter Health, HyLight | |
| 2026-10-17 | Chariot Claims | 10 million dollar Series A led by Silverton Partners, as the rebranded ClaimClam legal-tech platform scales automated matching of consumers to mass arbitration and class-action claims over hidden fees and hard-to-cancel subscriptions, building on more than 65,000 claims already processed toward an estimated 92 million dollars in settlements | Marklo, Siena, Rein Security, Peppermint | |
| 2026-10-16 | Salience Labs | 125 million dollar oversubscribed Series B led by Bullhound Capital, as the Oxford-spun-out photonics company wins new backing from AMD Ventures and Intel Capital for all-optical circuit switches meant to break the power and latency ceiling facing electronic switches as AI GPU clusters scale toward tens of thousands of chips | Navra, Type One Energy, Oratomic, Gallatin AI | |
| 2026-10-15 | Soufflé Therapeutics | 135 million dollar Series B led by Juvia Group, as the MIT bioengineer Robert Langer-founded biotech works to deliver RNA medicines to muscle and heart tissue, a problem that has stalled the entire siRNA drug class, backed by more than 3.5 billion dollars in big pharma partnerships before any program has reached the clinic | ICON, Pluto Security, Nous Research, Atomic Machines | |
| 2026-10-14 | Vitalize | 31 million dollar Series A led by Oak HC and FT, as the Y Combinator-backed startup unifying hospital staffing, scheduling, patient flow and capacity management expands after enterprise customers reported cutting manual scheduling work and premium labor spend | Gallatin AI, byteXL, Desible.ai, Credfix | |
| 2026-10-13 | Universal Quantum | 100 million dollar Series A co-led by DCVC and Firgun Ventures, a record raise for a UK quantum computing company, as the University of Sussex spinout races to prove its modular trapped-ion chiplet interconnect can out-scale newly public rivals Quantinuum and IonQ | Atlas Atomics, Type One Energy, Sabi, Catalyst | |
| 2026-10-12 | Manus | 500 million dollar funding round led by Boyu Capital and IDG Capital, the general AI agent's first raise since China blocked Meta's 2 billion dollar bid for the company and barred its founders from leaving the country, as Manus pursues a reported 4 billion dollar valuation on roughly 125 million dollars of annualized revenue | Oratomic, Matchpoint Therapeutics, Oxide Computer, Stuut | |
| 2026-10-11 | Arena | 200 million dollar Series B co-led by Lightspeed Venture Partners and Khosla Ventures at a 3.1 billion dollar valuation, as the company behind the Chatbot Arena leaderboard nearly doubles its valuation in ten months on roughly 100 million dollars of annualized revenue from selling AI evaluation and alignment benchmarking to labs and enterprises, while Scale AI's new Seal Showdown contests its neutral-referee position | Gallatin AI, Rein Security, Rivercell, TeddyHoldings.AI | |
| 2026-10-10 | Multiply Labs | 75 million dollar Series B led by Patrick Soon-Shiong's NantWorks with new investors AstraZeneca, Lingotto, Teradyne and Strange Ventures, as the decade-old biologics-manufacturing robotics company passes 100 million dollars raised on the strength of its first commercial sale, an up to 85 million dollar deal with Retro Biosciences, while competing against well-funded rivals Cellares and Ori Biotech to automate cell and gene therapy production | Zomint, Parakeet Health, OuterSignal, Efficient Computer | |
| 2026-10-09 | RougeTx | 58 million dollar Series A led by BioGeneration Ventures and Angelini Ventures with the European Investment Bank's Aurea facility and Kurma Partners also investing, as the Leiden University Medical Center spinout launches the first disease-modifying candidate for hereditary hemorrhagic telangiectasia, a bleeding disorder with no approved therapies, built on more than two decades of pericyte research | GMI Cloud, Varda Space Industries, doxx.net, Beyond Appliances | |
| 2026-10-08 | General Medicine | 120 million dollar Series B led by Andreessen Horowitz with Eli Lilly and Mercy Health joining, as the PillPack founders' online healthcare marketplace brings total funding to 152 million dollars less than three years after launch on hundreds of thousands of customers and an 80 Net Promoter Score | Noah, Nous Research, Buntar Aerospace, Monid | |
| 2026-10-07 | Vinci | 250 million dollar Series B at a 1.5 billion dollar valuation co-led by Advent, Temasek and Xora Innovation, as the Palo Alto physics foundation model startup jumps from a 46 million dollar seed and Series A disclosed last December to a tenfold valuation leap less than a year later, aiming its technology at chip design incumbents Cadence and Synopsys | Spiko, Hadrian, WhiteLab Genomics, Inbolt | |
| 2026-10-06 | Pandektes | 13.5 million euro Series A led by Munich's Alstin Capital, as the Copenhagen legal-research startup grows revenue sixfold and wins customers switching off LexisNexis, Westlaw, Beck and Karnov with an API-first legal data platform | OneByZero, Fleuret AI, Laki Power, RobCo | |
| 2026-10-05 | PaleBlueDot AI | 200 million dollar Series C at a 3.2 billion dollar valuation led by ComputeCore, as the Palo Alto AI compute platform nearly triples its valuation in under nine months on more than 5 billion dollars of signed customer contracts | Simple Energy, Elio Mortgage, Menos AI, SedMed | |
| 2026-10-04 | Flow Engineering | 50 million dollar Series B at a 750 million dollar valuation co-led by Valor Equity Partners and Atreides Management, as the AI-native systems-engineering platform for hardware teams grows to over 100 million requirements managed and adds General Motors, Anduril and Intuitive Machines as customers less than a year after its Series A | Miter, Kanu AI, Beltic, Satlyt | |
| 2026-10-03 | EliseAI | 350 million dollar round at a 4 billion dollar valuation led by Andreessen Horowitz and Bessemer Venture Partners, as the housing and healthcare conversational AI company nearly doubles its valuation in thirteen months on 200 million dollars of ARR and five straight years of 100 percent revenue growth | Kahua, Breye Therapeutics, Amara, Kuro | |
| 2026-10-02 | Armadin | 255.5 million dollar Series B co-led by Andreessen Horowitz and Accel at a 2.5 billion dollar valuation, as Mandiant founder Kevin Mandia's agentic attacker-swarm security platform runs live attack campaigns for Fortune 500 and government customers seven months after stealth | Foundational, Seeds Fincap, Numeral, Chamelio | |
| 2026-10-01 | General Intuition | 220 million dollar Series B at a 6.2 billion dollar valuation, nearly tripling in three months, as the AI foundation model startup trains action models on billions of gameplay clips from its own sister company Medal | Varda, Jeeves, Sand.ai, Arivihan | |
| 2026-09-30 | Tiny Health | Oversubscribed $33M Series B led by B Capital as the at-home microbiome testing company posts 1,624% three-year revenue growth and quadruples its practitioner-facing business | Modulate, erad, Baselayer, Ande | |
| 2026-09-29 | Instinct | $1B Series C led by Sequoia, Benchmark and Coatue at a $10B valuation, a roughly 4x jump in five weeks, as its text-message AI agent passes 100,000 users with 10% daily compounding growth | SiMa.ai, Quartermaster, Outmarket AI, Humanos | |
| 2026-09-28 | Solcoa Industries | $75M seed ($45M equity led by Bain Capital Ventures plus $30M JPMorgan-anchored debt) to build a 500-tonne Nevada plant using a novel rare-earth metalmaking process, aimed at breaking China's 95% grip on metallization | Clastix, Prevision Medicine, Spiich, Barq | |
| 2026-09-27 | Ultraviolette | $85M Series E led by Yali Capital and TDK Ventures; Bengaluru performance EV motorcycle maker plans US entry by 2027 on 4-5x revenue growth | Micro1, Kasvu Therapeutics, HIFI, Dextr AI | |
| 2026-09-26 | Island | $400M Series F led by Evolution Equity Partners at a $6.4B valuation, more than doubling its 2024 valuation as the enterprise browser expands into governing AI agents | Cyera, Confido, Heidi Health, Firecrawl | |
| 2026-09-25 | Ema | $77M Series B led by Creaegis, more than quadrupling its valuation as every existing backer doubled down and Wipro scales its AI Employees to 240,000+ workers | Ando, Kasvu Therapeutics, HIFI, Nuvah | |
| 2026-09-24 | TEKEVER | $580M Series D led by UC Investments and Baillie Gifford; Ukraine-proven AI surveillance drone maker hits $6.4B valuation on a new 400M pound UK Army contract | Enveda Biosciences, Basecamp Research, Numeral, Brahma AI | |
| 2026-09-23 | Verda | $189M oversubscribed Series B led by Emergence Capital; profitable Nordic GPU cloud crosses $1B valuation on $165M ARR | Snorkel AI, Nexstrom, MacroCycle, Demoverse | |
| 2026-09-22 | BCI-Sonics | RMB 200M (~$30M) Pre-Series A led by HSG and Yunqi Capital; non-invasive ultrasound brain-computer interface racing China's invasive BCI leaders and OpenAI-backed Merge Labs | Spott, HighLife, CellPoint, Benford | |
| 2026-09-22 | Amber Electric | €49M Series E led by Morgan Stanley's 1GT; automates 50%+ of Australia's home batteries, expanding VPP software into Europe via E.ON | Corridor, Paymob, Unit1 Studio, Drivn | |
| 2026-09-18 | TypeSafe AI | $40M seed led by DCVC; "System One" model returns typed decisions for software, not chat — built by RLHF co-inventor Diogo Almeida | Space Epoch, Facilo, Treble Technologies, DheyaTech | |
| 2026-09-17 | Exein | $270M Series C at $1.7B valuation (30x in 2 yrs); kernel-level security layer for robots, drones and autonomous machines | Anew Labs, Delos Data, CADDi, AIUC | |
| 2026-09-16 | Euclyd | €200M+ Series A; Samsung-backed (investor + manufacturer) AI inference chip built to out-efficiency Nvidia, chaired by ex-ASML CEO | Profound, Flam, ENCOS, Nutshell Therapeutics | |
| 2026-09-15 | Fortaegis | $50M oversubscribed Series A; quantum-safe security rooted in silicon, chaired by Quantinuum founder Ilyas Khan | Qupital, Tandem Health, Atomarine, UniqYou | |
| 2026-09-11 | Positron AI | $875M Series C at $5B valuation; memory-first inference chips challenging Nvidia's HBM lock-in | The Boring Company, Mach Industries, Rogo Technologies, Swish | |
| 2026-09-10 | Cognition AI | $2B+ Series E at $48B valuation; Devin autonomous coding agent nears $900M run-rate | DigitalPaani, Algomatic Dynamics, Limetax, Fundly.ai | |
| 2026-09-09 | Bluecore Energy | Floating nuclear reactor barges for ports; $50M seed just 2 months after stealth launch | QNu Labs, ARC Ride, Circolife, Hope Care | |
| 2026-09-08 | Pixxel | $100M Series C, India's largest spacetech round; building orbital AI data centers | Nua, Navana.ai, GalaxEye, Atoms (Kalanick) | |
| 2026-09-07 | Medulance | GPS-dispatched ambulance network raises ₹24 Cr Series A-2 | Comet, Mokobara, Kit (Speakeasy), XDOF |
Sources
- EU-Startups — Oxford spin-out Alethio Therapeutics raises €80.46 million Series A to advance targeted blood cancer therapies
- Cooley — Alethio Therapeutics Announces $90 Million Series A
- tech.eu — Denmark's EIFO joins TEKEVER's $580M Series D as company expands into Odense
- EU-Startups — With a new equity round in sight, Candi Solar secures €44 million for solar projects in India
- EU-Startups — Return secures €835 million financing to expand battery storage capacity in Germany
- Inc42 — Clinics On Cloud Bags ₹120 Cr To Take Its Health ATMs Global
- Prelude Therapeutics Investor Relations — Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
- Alethio Therapeutics — Company homepage